Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide

• Autor(a) principal: Muzzi, Alessandro
• Data de Publicação: 2019
• Outros Autores: Brozzi, Alessandro, Serino, Laura, Bodini, Margherita, Abad, Raquel, Caugant, Dominique, Comanducci, Maurizio, Lemos, Ana Paula, Gorla, Maria Cecilia, Křížová, Pavla, Mikula, Claudia, Mulhall, Robert, Nissen, Michael, Nohynek, Hanna, Simões, Maria João, Skoczyńska, Anna, Stefanelli, Paola, Taha, Muhamed-Kheir, Toropainen, Maija, Tzanakaki, Georgina, Vadivelu-Pechai, Kumaran, Watson, Philip, Vazquez, Julio A., Rajam, Gowrisankar, Rappuoli, Rino, Borrow, Ray, Medini, Duccio
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.18/6634
• topic: 4CMenB Vaccine; Genotyping; Neisseria meningitidis Serogroup B; Strain Coverage; gMATS; Infecções Respiratórias

Background: The Meningococcal Antigen Typing System (MATS) was developed to identify meningococcus group B strains with a high likelihood of being covered by the 4CMenB vaccine, but is limited by the requirement for viable isolates from culture-confirmed cases. We examined if antigen genotyping could complement MATS in predicting strain coverage by the 4CMenB vaccine. Methods: From a panel of 3912 MATS-typed invasive meningococcal disease isolates collected in England and Wales in 2007-2008, 2014-2015 and 2015-2016, and in 16 other countries in 2000-2015, 3481 isolates were also characterized by antigen genotyping. Individual associations between antigen genotypes and MATS coverage for each 4CMenB component were used to define a genetic MATS (gMATS). gMATS estimates were compared with England and Wales human complement serum bactericidal assay (hSBA) data and vaccine effectiveness (VE) data from England. Results: Overall, 81% of the strain panel had genetically predictable MATS coverage, with 92% accuracy and highly concordant results across national panels (Lin's accuracy coefficient, 0.98; root-mean-square deviation, 6%). England and Wales strain coverage estimates were 72-73% by genotyping (66-73% by MATS), underestimating hSBA values after four vaccine doses (88%) and VE after two doses (83%). The gMATS predicted strain coverage in other countries was 58-88%. Conclusions: gMATS can replace MATS in predicting 4CMenB strain coverage in four out of five cases, without requiring a cultivable isolate, and is open to further improvement. Both methods underestimated VE in England. Strain coverage predictions in other countries matched or exceeded England and Wales estimates.